PAREXEL AND SPOTFIRE TO PREVIEW INFORMATICS SOFTWARE FOR CLINICAL RESEARCH AT 36TH ANNUAL DIA MEETING
BOSTON, MA, and CAMBRIDGE, MA, June 12, 2000 — PAREXEL International Corporation (Nasdaq: PRXL) and Spotfire, Inc. today announced that they will demonstrate integration of PAREXEL’s Web-based, data warehousing offering, ParXware™ and Spotfire’s decision analytics platform, Spotfire.net™ to provide a comprehensive clinical trial data analysis solution that they will preview at the 36th Annual Drug Information Association (DIA) Meeting in San Diego, California this week.
Specifically, PAREXEL will demonstrate the benefits of integrating various clinical trial data - including associated medical images - in ParXware™ with the Spotfire.net™ analytics platform. Within the multi-dimensional, interactive environment of Spotfire.net™, users can quickly and easily access large amounts of disparate data from ParXware™ and analyze the data to make visual comparisons, view trends and anomalies, and draw conclusions quickly. Data from electronic lab test results, EKGs and MRIs can also be delivered from ParXware™ for analysis in Spotfire.net™. In addition to the powerful analytical capabilities of this integrated clinical trial solution, users can also benefit from its enterprise-wide capabilities to access, analyze and publish data within a collaborative, connected technical community.
"We are excited about the opportunity to preview a uniquely integrated clinical trial analysis solution that supports in-depth, open exploration," said Mark A. Goldberg, M.D., Senior Vice President of PAREXEL’s Advanced Technology and Informatics Business Unit. "The data warehousing capabilities of ParXware™ combined with the integrated decision analytics platform of Spotfire.net™ will illustrate how customers can make faster, more informed decisions."
"We are very pleased to be working with PAREXEL, one of the largest contract research organization in the world, as we expand the application of our decision support tools into the clinical development arena," said Joseph F. Donahue, Spotfire Vice President, Worldwide Life Sciences Market. "This integration gives users the means to rapidly access, analyze and publish data from increasingly disparate data sources in order to accelerate the discovery of life-saving drugs."
This release may contain "forward-looking" statements regarding future results and events, including statements regarding expected financial results, future growth and customer demand. The Company's actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: the cancellation or delay of contracts; the Company's dependence on certain industries and clients; the Company's ability to manage growth and its ability to attract and retain employees; the Company's ability to complete additional acquisitions and to integrate newly acquired businesses; government regulation of certain industries and clients; competition and consolidation within the pharmaceutical industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations. These factors and others are discussed more fully in the section entitled "Risk Factors" of the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2000.
PAREXEL is one of the largest contract pharmaceutical outsourcing organizations in the world, providing a broad range of knowledge-based contract research, medical marketing and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. With a commitment to providing solutions that accelerate time-to-market and peak market penetration, PAREXEL has developed significant expertise in clinical trials management, data management, biostatistical analysis, medical marketing, clinical pharmacology, regulatory and medical consulting, industry training and publishing and other drug development consulting services. The Company’s integrated services, therapeutic area depth and sophisticated information technology, along with its experience in global drug development and product launch services, represent key competitive strengths. Headquartered near Boston, MA, PAREXEL operates in 43 locations throughout 29 countries around the world, and has approximately 4,275 employees.